Baxter International Inc. and Halozyme Therapeutics, Inc., today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].

HyQvia is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG. The majority of PI patients today receive intravenous infusions in a doctor's office or infusion center, and current subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment.

For more details, go to: http://www.baxter.com/press_room/press_releases/2014/09_12_14_hyqvia.html